Discovery STREAM

1. BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D. 2/26/2023

   Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it's backed to pioneer a new category of genetic medicine it calls gene writing. The Business of Biotech caught up with Severino at the JP Morgan Healthcare Conference in San Francisco last month. We learned what lured him away from leadership positions at Merck, Amgen, and AbbVie, how gene writing differs from gene therapy and gene editing, why the team at Tessera believes its technologies can write and rewrite DNA at the scales necessary to cure most genetic diseases, and where he plans to take the company from here. 

2. Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin 9/7/2023

   Core to the clinical-stage biopharma Life Biosciences belief set is that "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.”

3. How To Best Optimize mRNA Production Workflows 4/11/2023

   Multiple steps in the mRNA manufacturing process can appear more complex than they have to be. Learn how to simplify your approach and produce the best possible mRNA vaccines and therapeutics.

4. Elucidating The Role Of IL-18 In NSCLC Integrated Analysis 1/23/2025

   Hear how imaging mass cytometry, CyTOF, and single-cell sequencing unlock the secrets of the tumor microenvironment. Discover new insights into IL-18 and its impact on non-small cell lung cancer.

5. Validation Of An LCMS Hybrid Assay With EVOSEP Cleanup 2/17/2025

   By leveraging this innovative combination, the assay achieves detection limits comparable to traditional methodologies while enhancing overall efficiency and reliability.

6. Is The Sensitivity Of Optical Biosensors Important? 2/17/2022

   Explore why the sensitivity of optical biosensors is important for not just small molecules or fragment-based interactions but also for larger molecular entities.

7. How J&J Is Tackling Alzheimer's Disease With Fiona Elwood, Ph.D. 9/22/2025

   Fiona Elwood, Ph.D., VP and Neurodegeneration Disease Area Stronghold Leader at Johnson & Johnson, explains the company’s modality-agnostic approach to treating Alzheimer’s disease in this episode of Better Biopharma.

8. Meet Your Bioprocess Sidekick For Cell Culture Media Analysis 6/10/2022

   You need rapid and reliable nutrient profiles to make informed decisions, and waiting on that data has detrimental effects on your process. See how REBEL fills the gap.

9. Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D. 10/20/2025

   In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease.

10. Bio Career Moves With Codagenix's Johanna Kaufmann, Ph.D. 10/11/2023

    On this week's episode of the Business of Biotech, Dr. Johanna Kaufmann gives us an intimate retrospective on her career to date, sharing stories about her rapid ascension from Scientist 1 to executive leadership. We dig into her wild ride through M&A, her time at GSK, and the professional and personal development regimens she subscribes to.